Association between tissue factor, its pathway inhibitor and oxidative stress in peritoneal dialysis patients

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 5, 2007, Pages 467-471

  Pawlak, Krystyna ^a   Pawlak, Dariusz ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetes mellitus; Oxidative stress; Peritoneal dialysis; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; MALONALDEHYDE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; THROMBOSIS;

ADULT; BIOLOGICAL MARKERS; DIABETES MELLITUS; FEMALE; HUMANS; LIPOPROTEINS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; SUPEROXIDE DISMUTASE; THROMBOPLASTIN;

EID: 34250843712     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3281a3bee9     Document Type: Article

References (23)

1. Prichard S. Cardiovascular risk in peritoneal dialysis. Contrib Nephrol 2003; 140:82-90.
2. Lameire N, Bernaert P, Lambert M-C, Vijt D. Cardiovascular risk factors and their management in patients on continuous ambulatory peritoneal dialysis. Kidney Int 1994; 46 (Suppl 48):S31-S38.
3. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62:1524-1538.
4. Roob JM, Rabold T, Hayn M, Khoschsorur G, Resch U, Holzer H, Winklhofer-Roob BM. Ex vivo low-density lipoprotein oxidizability and in vivo lipid peroxidation in patients on CAPD. Kidney Int 2001; 59 (Suppl 78):S128-S136.
5. Galli F, Buoncristiani U, Rovidati S, Albertini MC, Carobi C, Canestrari F. Lipoperoxidation and glutathione-dependent enzymes in uremic anemia of CAPD patients [letter]. Nephron 1997; 76:363.
6. Bonnefont-Rousselot D, Jaudon MC, Issad B, Cacoub B, Congy F, Jardel C, et al. Antioxidant status of elredy chronic renal patients treated by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1997; 12:1399-1405.
7. Malyszko J, Malyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001; 21:158-165.
8. Ozdemir FN, Guz G, Sezer S, Arat Z, Turan M, Haberal M. Atherosclerosis risk is higher in continuous ambulatory peritoneal dialysis patients than in hemodialysis patients. Artif Organs 2001; 25:448-452.
9. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188:180-188.
10. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004; 44:2293-2300.
11. Zemanova P, Opatrny K Jr, Opatrna S, Vit L, Sefrna F, Racek J. Tissue factor, its pathway inhibitor, and metabolic disturbances in long-term peritoneal dialysis. Kidney Blood Press Res 2003; 26:368-375.
12. Malgorzewicz S, Lichodziejewska-Niemierko M, Rutkowski B, Lysiak-Szydlowska W. Nutritional status and oxidative processes in diabetic and nondiabetic peritoneal dialysis patients. J Ren Nutr 2004; 14:242-247.
13. Londero D, Lo Greco P. Automated high-performance liquid chromatographic separation with spectrofluorometric detection of a malondialdehyde-tiobarbituric acid adduct in plasma. J Chromatogr A 1996; 729:207-210.
14. Khechai F, Ollivier V, Bridey F, Amar H, Hakim J, de Prost D. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation. Arterioscler Thromb Vasc Biol 1997; 17:2885-2890.
15. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ. Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 2006; 49:766-774.
16. Rathaus M, Bernheim J. Oxygen species in the microvascular environment: regulation of vascular tone and the development of hypertension. Nephrol Dial Transplant 2002; 17:216-221.
17. Pawlak K, Pawlak D, Mysliwiec M. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 2005; 38:700-705.
18. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidants enzymes and human diseases. Clin Biochem 1999; 32:595-603.
19. Morrissey JH. Tissue factor: an enzyme cofactor and true receptor. Thromb Haemost 2001; 86:66-74.
20. Warner BB, Stuart L, Gebb S, Wispe JR. Redox regulation of manganase superoxide dismutase. Am J Physiol 1996; 271:L150-L158.
21. Brisseau GF, Dackiw APB, Cheung PYC, Christie N, Rotstein OD. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85:1025-1035.
22. Halliwell B. The role of oxygen radicals in human disease, with particular reference to vascular system. Haemostasis 1993; 23 (Suppl 1):118-126.
23. de Valk B, Marx JJM. Iron, atherosclerosis and ischemic heart disease. Arch Intern Med 2000; 159:1542-1548.